Rankings
▼
Calendar
AMPH
Amphastar Pharmaceuticals, Inc.
$894M
Q3 2022 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$120M
+7.1% YoY
Gross Profit
$59M
48.7% margin
Operating Income
$23M
19.3% margin
Net Income
$16M
13.2% margin
EPS (Diluted)
$0.30
QoQ Revenue Growth
-2.7%
Cash Flow
Operating Cash Flow
$20M
Free Cash Flow
$15M
Stock-Based Comp.
$4M
Balance Sheet
Total Assets
$727M
Total Liabilities
$222M
Stockholders' Equity
$505M
Cash & Equivalents
$157M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$120M
$112M
+7.1%
Gross Profit
$59M
$51M
+14.3%
Operating Income
$23M
$25M
-6.2%
Net Income
$16M
$30M
-46.3%
Revenue Segments
Research and development services
$800,000
100%
Geographic Segments
UNITED STATES
$118M
98%
FRANCE
$2M
1%
CHINA
$719,000
1%
← FY 2022
All Quarters
Q4 2022 →
AMPH Q3 2022 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena